25,000 Shares in Billiontoone, Inc. $BLLN Bought by Seven Grand Managers LLC

Seven Grand Managers LLC bought a new position in Billiontoone, Inc. (NASDAQ:BLLN) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $2,046,000. Seven Grand Managers LLC owned 0.05% of Billiontoone as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of BLLN. Geode Capital Management LLC bought a new position in shares of Billiontoone during the 4th quarter valued at about $6,716,000. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Billiontoone during the 4th quarter valued at about $82,000. Sigma Planning Corp bought a new position in shares of Billiontoone during the 4th quarter valued at about $409,000. Renaissance Capital LLC bought a new position in shares of Billiontoone during the 4th quarter valued at about $201,000. Finally, UBS Group AG bought a new position in shares of Billiontoone during the 4th quarter valued at about $2,586,000.

Billiontoone Trading Up 7.7%

Shares of NASDAQ BLLN opened at $91.02 on Thursday. The firm’s 50-day simple moving average is $82.35. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. The stock has a market cap of $4.19 billion and a PE ratio of 165.49. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $95.81 million. The firm’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.39) earnings per share. On average, equities analysts predict that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on BLLN shares. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Guggenheim increased their price objective on shares of Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. BTIG Research dropped their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. JPMorgan Chase & Co. increased their price objective on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, Wells Fargo & Company dropped their price objective on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $125.29.

Billiontoone Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.